Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Clovis Oncology, Inc.
  6. Summary
    CLVS   US1894641000

CLOVIS ONCOLOGY, INC.

(CLVS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
0.761(c) 0.7815(c) 0.8292(c) 0.7814(c) 0.7401(c) Last
5 630 156 3 824 751 4 577 296 5 779 555 3 843 944 Volume
+1.64% +2.69% +6.10% -5.76% -5.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 155 M - -
Net income 2022 -229 M - -
Net Debt 2022 312 M - -
P/E ratio 2022 -0,43x
Yield 2022 -
Sales 2023 211 M - -
Net income 2023 -174 M - -
Net Debt 2023 326 M - -
P/E ratio 2023 -0,79x
Yield 2023 -
Capitalization 106 M 106 M -
EV / Sales 2022 2,70x
EV / Sales 2023 2,05x
Nbr of Employees 413
Free-Float 98,6%
More Financials
Company
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent... 
Read more
More about the company
Ratings of Clovis Oncology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CLOVIS ONCOLOGY, INC.
05/11TRANSCRIPT : Clovis Oncology, Inc. Presents at Bank of America 2022 Healthcare Conference,..
CI
05/05CLOVIS ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/05Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
BU
05/04TRANSCRIPT : Clovis Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on C..
BU
05/04CLOVIS : Q1 Earnings Snapshot
AQ
05/04Earnings Flash (CLVS) CLOVIS ONCOLOGY Reports Q1 Loss $-0.44, vs. Street Est of $-0.49
MT
05/04Clovis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
04/28Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 20..
BU
04/20Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Confe..
BU
04/08Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AA..
BU
04/08Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® at the AACR Annual Me..
CI
03/31SECTOR UPDATE : Health Care Stocks Sidestep Steeper Thursday Market Losses
MT
03/31SECTOR UPDATE : Health Care Stocks Mixed in Thursday Trading
MT
03/31SECTOR UPDATE : Health Care
MT
More news
News in other languages on CLOVIS ONCOLOGY, INC.
05/04Clovis Oncology, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2..
04/08Clovis Oncology souligne les présentations sur le FAP-2286 et le Rubraca® (Rucaparib) l..
03/31MISE À JOUR SECTORIELLE : Les actions du secteur de la santé évitent des pertes de marché ..
03/31Clovis Oncology déclare que le traitement du cancer ovarien a atteint le critère princi..
03/31La Bourse s'apprête à ouvrir à plat ; les inscriptions au chômage sont plus élevées que..
More news
Analyst Recommendations on CLOVIS ONCOLOGY, INC.
More recommendations
Chart CLOVIS ONCOLOGY, INC.
Duration : Period :
Clovis Oncology, Inc. Technical Analysis Chart | CLVS | US1894641000 | MarketScreener
Technical analysis trends CLOVIS ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 0,74 $
Average target price 2,25 $
Spread / Average Target 204%
EPS Revisions
Managers and Directors
Patrick J. Mahaffy President, Chief Executive Officer & Director
Daniel W. Muehl Principal Accounting Officer & Senior VP-Finance
Ginger L. Graham Chairman
Lindsey Rolfe Senior Vice President-Clinical Development
Thomas Fuglsang Harding Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
CLOVIS ONCOLOGY, INC.-72.69%106
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169